Company Profile

Bolden Therapeutics Inc
Profile last edited on: 5/12/2023      CAGE: 8FT97      UEI: PKW8T8LGCNH4

Business Identifier: First-in-class therapeutics to treat diseases of central nervous system
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

225 Dyer Street Floor 2
Providence, RI 02903
   (617) 669-4932
Location: Single
Congr. District: 02
County: Providence

Public Profile

With for firm's corporate headquarters in Rhode Island but having research facilities in Cambridge MA, Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimer’s disease and ischemic stroke. The firm is structured around the scientific founders having determined a key molecular pathway to promote the birth of new neurons (neurogenesis) in the adult brain. In a proprietary mouse model Bolden has established proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory believed to play an important role in learning and memory. Diminished neurogenesis can contribute to cognitive dysfunction and memory impairment, and this phenomenon is observed in multiple neurodegenerative diseases and neurological conditions. In addition, neurogenesis has been implicated as important for functional recovery following traumatic brain injury and ischemic stroke.There are potentially various potential clinical applications for neurogenesis-promoting therapies around which the firm is organized includiing - but not limited to - Alzheimer’s disease and related dementias, ischemic stroke, treatment-resistant depression, Huntington’s disease, Parkinson’s disease, traumatic brain injury, and cognitive impairment following chemotherapy.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Johnny Page -- Co-Founder & CEO

  Jill Dvornik -- Research Scientist

  Justin R Fallon -- Scientific Founder

  Stephen Salloway

  Anne Valat -- Research Scientist

  Ashley E Webb -- Scientific Founder

Company News

There are no news available.